Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VITALIZE in relapsed/refractory diffuse large B-cell lymphoma
2021-003712-27Phase 2Active
- Sponsor
- IMV
- Start
- Mar 2022
- Modality
- Small Molecules, Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial in diffuse large B-cell lymphoma (DLBCL) comparing DPX-Survivac + pembrolizumab with DPX-Survivac + pembrolizumab + cyclophosphamide (2 arms). Primary endpoint: Objective response rate. Started Mar 2022; status: active.
02
Drugs
03
Conditions
diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on 2021-003712-27.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-003712-27.